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A simple, high-throughput, 
colourimetric, field applicable loop-mediated 
isothermal amplification (HtLAMP) assay 
for malaria elimination
Sumudu Britton1,2*, Qin Cheng3, Colin J. Sutherland4 and James S. McCarthy1,2
Abstract 
Background: To detect all malaria infections in elimination settings sensitive, high throughput and field deployable 
diagnostic tools are required. Loop-mediated isothermal amplification (LAMP) represents a possible field-applicable 
molecular diagnostic tool. However, current LAMP platforms are limited by their capacity for high throughput.
Methods: A high-throughput LAMP (HtLAMP) platform amplifying mitochondrial targets using a 96-well microtitre 
plate platform, processing 85 samples and 11 controls, using hydroxynaphtholblue as a colourimetric indicator was 
optimized for the detection of malaria parasites. Objective confirmation of visually detectable colour change results 
was made using a spectrophotometer. A dilution series of laboratory-cultured 3D7 Plasmodium falciparum parasites 
was used to determine the limit of detection of the HtLAMP assay, using P. falciparum (HtLAMP-Pf ) and Plasmodium 
genus (HtLAMP-Pg) primers, on whole blood and filter paper, and using different DNA extraction protocols. The diag-
nostic accuracy of HtLAMP was validated using clinical samples from Papua New Guinea, Malaysia, Ghana and The 
Gambia and its field applicability was evaluated in Kota Marudu district hospital, Sabah, Malaysia.
Results: The HtLAMP assay proved to be a simple method generating a visually-detectable blue and purple colour 
change that could be objectively confirmed in a spectrophotometer at a wavelength of 600 nm. When compared 
with PCR, overall HtLAMP-Pg had a sensitivity of 98 % (n = 260/266, 95 % CI 95–99) and specificity 83 % (n = 15/18, 
95 % CI 59–96). HtLAMP-Pf had a sensitivity of 97 % (n = 124/128, 95 % CI 92–99) and specificity of 96 % (n = 151/157, 
95 % CI 92–99). A validation study in a regional hospital laboratory demonstrated ease of performance and interpre-
tation of the HtLAMP assay. HtLAMP-Pf performed in this field setting had a sensitivity of 100 % (n = 17/17, 95 % CI 
80–100) and specificity of 95 % (n = 123/128, 95 % CI 90–98) compared with multiplex PCR. HtLAMP-Pf also per-
formed well on filter paper samples from asymptomatic Ghanaian children with a sensitivity of 88 % (n = 23/25, 95 % 
CI 69–97).
Conclusion: This colourimetric HtLAMP assay holds much promise as a field applicable molecular diagnostic tool for 
the purpose of malaria elimination.
Keywords: Loop mediated isothermal amplification, LAMP, Elimination, High throughput, Diagnosis, Malaria
© 2015 Britton et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Malaria elimination is an ambitious but enticing 
goal. Elimination is defined as “interrupting local 
mosquito-borne malaria transmission in a defined geo-
graphical area, i.e. zero incidence of locally contracted 
cases, although imported cases will continue to occur” 
[1]. By definition, malaria elimination is fundamentally 
different from malaria control, as the focus shifts from 
detection of symptomatic patients to detection and clear-
ance of all infections. This includes active case detection 
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of asymptomatic persons with sub-patent parasitaemia 
[2], subjects who have been shown to be able to support 
ongoing malaria transmission [3].
For P. falciparum and P. vivax, passive and active detec-
tion of infection in the field have relied on two diagnostic 
tools: thick and thin blood film microscopy, and immu-
nochromatographic detection of circulating parasite anti-
gens using rapid diagnostic tests (RDT). While expert 
microscopy has been shown to have 100 % sensitivity at 
thick film parasite densities of 50 parasites/µL, sensitiv-
ity decreases significantly under operational field condi-
tions [4]. Furthermore, studies in both Africa and Asia 
show that microscopy alone will fail to identify a sub-
stantial proportion of asymptomatic infections caused by 
all Plasmodium species, compared to detection by PCR 
[3]. It has been suggested that the proportion of submi-
croscopic infections is greater in areas where malaria 
elimination programmes are in place [5]. Such infections 
remain transmissible, and thus pose a threat to malaria 
elimination [6]. The success of malaria elimination pro-
grams will, therefore, critically depend on successful 
identification and treatment of all infected individuals. 
This requires high performance diagnostic tools, as out-
lined by the malERA consultative group [7]. The target 
sensitivity has recently been updated by WHO to specify 
a detection limit of 2 parasites/µL [8], a level substantially 
lower than expert microscopy.
Loop-mediated isothermal amplification (LAMP) is a 
nucleic acid detection technology that has the potential 
to significantly improve malaria field diagnostics, par-
ticularly in elimination settings. LAMP differs from PCR 
in several critical ways. Firstly, it is an isothermal process 
relying on the Bacillus stearothermophilus (Bst) polymer-
ase enzyme. It does not require the cyclical temperature 
changes [9] necessary for PCR. This facilitates field adap-
tation of LAMP platforms. Secondly, a positive LAMP 
reaction results in the formation of a magnesium pyroph-
osphate precipitate which can be visually detected, by 
turbidimetry [9] or using metal ion indicators, such as 
calcein [10], hydroxynaphthol blue [11] and pico-green 
[12]. LAMP end products have also been visualized using 
melt curve analysis [13], a bioluminescent output in real 
time (BART) [14], a lateral flow dipstick [15] and a port-
able fluorescence detection unit (realAmp) [16].
Since its first description in 2001 [9] LAMP has been 
applied to the detection of a wide variety of bacterial [17, 
18], viral [19], fungal [20] and parasitic [21] organisms, in 
particular to facilitate diagnosis of infection in resource 
limited settings. There has been a significant amount of 
research effort invested into adapting LAMP for diagno-
sis of malaria. LAMP has been used for the detection of 
P. falciparum using crudely extracted DNA from whole 
blood [22], or using a rapid boil and spin method [23]. 
Subsequently, LAMP has been used to identify all Plas-
modium species [24], including P. knowlesi [25, 26], and 
LAMP primers have been optimized to improve the sen-
sitivity with which P. falciparum [23, 27] and P. vivax [28, 
29] can be detected. Commercially available Loopamp 
kits (Eiken Chemical co) have been validated for detec-
tion of P. falciparum [30], including low density infec-
tions [31] and for the indirect detection of P. vivax using 
a combination of pan-genus and P. falciparum-specific 
LAMP primers [32]. However, as Hsiang et  al. noted, 
obtaining a high throughput LAMP assay would appear 
to be an important step in making the technology more 
widely applicable [33] for the purpose of malaria elimi-
nation. Although assay time for most LAMP platforms 
is rapid at 60–90 min, sample throughput is restricted by 
the platform used. For example, the LoopAmp kits (Eiken 
Chemical Co) used in the turbidimeter (Eiken Chemical 
Co) has a capacity of only 16 samples, while the kits used 
with a heatblock and ultraviolet lamp has capacity of 46 
samples [31]. The demonstration that colorimetric detec-
tion of LAMP products provides acceptable diagnostic 
accuracy [11] suggests that this could be adapted to pro-
duce a multi-well, low-cost format for the detection of 
malaria parasites by LAMP.
This paper describes development of a platform for 
malaria LAMP that increases the throughput of the 
assay, and simplifies DNA extraction and sample analy-
sis, resulting in improved field applicability. Validation of 
the platform was carried out by investigating its diagnos-
tic accuracy using PCR as a gold standard as it is highly 
sensitive and widely available in reference laboratories for 
detecting low-level parasitaemia.
Methods
Plasmodium parasite and clinical samples
A tenfold dilution series of laboratory-cultured 3D7 P. 
falciparum parasites was prepared in 50  % haematocrit 
blood using initial samples with parasitaemia adjusted to 
1 and 0.5 %, as determined by microscopic examination 
of thin blood films. The number of parasites per microli-
tre was calculated using an estimate of 5 × 106 red cells/
µL to create a dilution series of samples ranging from 
5000 to 0.5 parasites/µL. Four 5 µL blood spots at each 
dilution were dried for 48 h on blotting paper (Whatman 
3MM) before being stored at 4 °C with desiccant. Whole 
blood was stored at −20 °C.
For assay validation, clinical samples were retrospec-
tively made available from the following clinical trials: 
(1) filter paper samples (n  =  25) from asymptomatic 
children from Ghana [31, 34], (2) whole blood samples 
(n  =  97) from symptomatic children from The Gam-
bia [35], (3) filter paper samples (n  =  42) from symp-
tomatic persons from a high prevalence malaria region 
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in Papua New Guinea (PNG) and (4) filter paper sam-
ples (n  =  145) from a case–control study [36] under-
taken in region of mixed malaria species infections in 
Sabah, Malaysia. The inclusion and exclusion criteria 
for each of these studies are outlined in their respective 
publications.
The study protocols for each study were approved 
by the Ghana Health Service Ethics Committee (pro-
posal #GHS-ERC-08/7/10) and the Ethics Committee of 
the London School of Hygiene and Tropical Medicine 
(proposal #5775), Joint Gambia Government/Medi-
cal Research Council Ethics Committee (re. 2002/910), 
QIMR Berghofer Medical Research Institute Human 
Research Ethics Committee (P2119), the Malaysian Med-
ical Research Ethics Committee and Menzies School of 
Health Research, respectively.
DNA extraction from filter paper
The chelex method for DNA extraction from filter paper 
[37] was further optimized to improve turnaround time. 
Briefly, 6  mm filter paper disc punches, correspond-
ing to 5  µL of blood, were incubated in 0.5  % saponin 
in PBS either overnight (chelex standard protocol) or 
for 2 h (chelex rapid protocol), centrifuged for 2 min at 
4000 rpm, supernatant discarded, washed in PBS, centri-
fuged for 2 min at 4000 rpm, heated at 98  °C in 150 µL 
of 6 % chelex (Sigma Aldrich, CAS 8047-15-2) for 30 min 
and centrifuged for 3  min at 4000  rpm. The resultant 
100 µL supernatant was stored at −20 °C.
DNA extraction from whole blood
For whole blood, the chelex method [38] was further 
evaluated in two modified protocols. Briefly, 5  µL of 
whole blood was mixed with either 200 µL of nuclease-
free water for 20  min at room temperature (WB-chelex 
protocol) or 200  µL of 0.5  % saponin, and incubated at 
37 °C for 30 min (WB-chelex saponin protocol). Samples 
were then centrifuged for 3  min at 10,000  rpm, super-
natant discarded, the pellet heated at 98  °C in 150  µL 
of 6  % chelex for 30  min and centrifuged for 3  min at 
10,000  rpm. The resultant supernatant was stored at 
−20 °C. For both extraction protocols, three volumes of 
blood, 5, 10 and 20 µL, were assessed.
DNA extraction from clinical samples
The Gambia whole blood samples were extracted using 
the WB-chelex protocol on 5 µL of blood. The filter paper 
samples from Ghana were extracted using the FP-chelex 
standard protocol. The PNG and Sabah filter paper sam-
ples were extracted using the FP-chelex rapid protocol. 
The differences in methods used for clinical sample pro-
cessing reflect the different sample sets used to validate 
each of the extraction protocols.
High‑throughput LAMP (HtLAMP) method
High throughput (HtLAMP) was performed in a 96-well 
microtitre plate as described [11], with some modifica-
tions. The assays were performed in a standard u-bottom 
microtitre plate (Sterihealth) covered with a clear dis-
posable plate cover (Eppendorf ). Each plate was able to 
process 85 samples allowing for 9 negative and 2 posi-
tive controls. Reactions were performed in 25  µL total 
volume containing 1X buffer (20 mM Tris HCL pH 8.8, 
10 mM KCl, 8 mM MgSO4, 10 mM NH4SO4), 1.25 mM 
each dNTP, 3.55  µM each Pf869FIP/BIP, 1.78  µM 
each Pf869LF/LBn, 0.2  µM each Pf869F3/B3, 1.18  µM 
each PgID19FIP/BIP, 0.59  µM each PgID19 LF/LB and 
0.15 µM each PgID19 F3/B3, 120 µM Hydroxynaphthol-
blue (Fluka, CAS number 63451-35-4) and 8 units Bst 
polymerase (New England Biolabs, Ipswich, MA, USA). 
Primer sequences for Pf869 and PgID19 were as pub-
lished by Polley et al. [23] except Pf869LBn GTTGAGA 
TGGAAACAGCCGG. Microtitre plates were incu-
bated in a water bath at 65 °C for 40 min before the col-
our change and precipitate in each well were recorded. 
Blue colour change with a visible precipitate was read 
as a positive result and purple colour change without a 
precipitate was read as a negative result (Fig. 1). Positive 
and negative samples were read by a single person who 
was blinded to the multiplex PCR results for the samples 
being analysed.
Performance of HtLAMP in a laboratory setting with 
limited resources involved storing reagents in a freezer 
at −20 °C and preparation of the mastermix as required 
for performance of each HtLAMP assay. Efforts to pre-
vent contamination were based on physical separation of 
DNA extraction from mastermix preparation areas and 
spectrophotometry, combined with stringent attention to 
Fig. 1 HtLAMP colour change associated with hydroxynaphtholblue 
(HNB). Left clear, purple colour, without precipitate = negative. Right 
Blue colour change with cloudy precipitate = positive
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hand hygiene and glove and gown changes between the 
different assay areas.
Limit of detection of HtLAMP
The limit of detection (LOD) for the HtLAMP assay was 
determined by performing HtLAMP-Pg and HtLAMP-
Pf on duplicate samples at each dilution. Filter paper 
extracted using the two DNA extraction protocols and 
whole blood 5, 10 and 20  µL extracted using the two 
DNA extraction protocols were evaluated. The LOD was 
determined to be the lowest dilution (containing the least 
parasite material) at which both duplicates were positive 
by HtLAMP.
Factors affecting Hydroxynaphthol blue (HNB)
HNB is a metal ion indicator that is sensitive to changes 
in pH as well as concentrations of the divalent cations 
magnesium and calcium. Using pH calibration buffers at 
pH 4.0, 7.0 and 10.0 plus hydrochloric acid, 8 samples of 
different pH were produced and tested with HNB. Result-
ing colour changes were recorded visually. Magnesium 
sulphate (MW 246.68 g/mol) and calcium chloride (MW 
110.99 g/mol) were used to make 5 samples of concentra-
tions varying from 1 to 0.001 M. These were also tested 
with HNB and resulting colour changes were recorded 
visually.
Spectrophotometer for determining threshold of positive 
result
A plate spectrophotometer (PowerwaveXS2 software ver-
sion 2.00.18) was used in order to determine a threshold 
value to objectively differentiate a positive from a nega-
tive HtLAMP result and demonstrate the reliability of 
visually detectable colour change in determining a posi-
tive and negative sample. Using a P. falciparum 3D7 DNA 
dilution series, HtLAMP mastermix reagents both with 
and without HNB were placed in the microtitre plate. 
Nuclease free water was used as the no template negative 
control. Following incubation in a water bath at 65 °C for 
40  min, the microtitre plate was read visually to docu-
ment cloudy and blue positive reactions and clear and 
purple negative reactions in the wells containing HNB. 
The presence and absence of cloudy white precipitate was 
recorded in the wells without HNB. The microtitre plate 
was then read in the spectrophotometer across the vis-
ible light spectrum from 300 to 700  nm to identify the 
wavelengths that best discriminated positive and negative 
samples both with and without HNB.
The optical density (OD) value with the best discrimi-
nation of HNB related positive and negative colour 
change as well as presence and absence of magnesium 
pyrophosphate precipitate was then used to read each 
well. The threshold value for a positive reaction was 
calculated using the mean plus two standard deviations 
of the no template control (NTC) wells. This threshold 
value was then subtracted from the OD reading for each 
well to obtain a positive or negative numerical value. The 
presence of a visible blue colour change with presence of 
cloudy precipitate was mandatory for a sample to be pos-
itive. A positive numerical OD value was used to confirm 
the visually determined positive result. A sample that was 
purple and clear was considered a negative result with a 
negative OD value confirming this result. Samples with 
only a positive OD result without corresponding col-
our change and precipitate were considered negative. 
Therefore, results were recorded based on their colour 
change with OD values being used to confirm the visu-
ally detected result. Only samples with the appropriate 
colour change and corresponding OD result were con-
sidered true positives or true negatives for the purpose of 
statistical analysis.
Nested PCR
For both whole blood and filter paper DNA extraction 
methods, the limit of detection was determined by com-
parison of HtLAMP to nested PCR as described by Snou-
nou et  al. [39]. PCR reactions were performed in 20 µL 
total volume containing 1X buffer, 2 mM MgCl2, 200 µM 
dNTPs, 200 µM primer mix (rPLU5new/rPLU6 for nest 
1 and rFAL1/rFAL2 for nest 2) and 0.5 U Taq polymerase 
(Bioline). The PCR amplification products were visual-
ized by gel electrophoresis.
Multiplex PCR
PCR was used as the reference standard for analysing the 
diagnostic accuracy of the HtLAMP platform given its 
sensitivity. Multiplex PCR (mPCR), which has an LOD 
of 0.02–0.05 parasites/µL as described by Padley et  al. 
[40], and had already been performed on these samples 
as part of their respective studies, was used as the gold 
standard reference test for comparison of HtLAMP-Pf 
and HtLAMP-Pg in the analysis of the PNG and Sabah 
samples. Nested PCR [39] was performed on the Ghana 
and Gambia samples.
Statistics
Sensitivity and specificity of HtLAMP was calculated 
against mPCR and nested PCR. Sensitivity =  true posi-
tives/(true positives  +  false negatives) and specific-
ity  =  true negatives/(true negatives  +  false positives). 
The 95  % confidence intervals were calculated using an 
online calculation tool [41].
Feasibility of field application of htLAMP
The HtLAMP assay field applicability was assessed 
by performing the assay in a regional hospital in Kota 
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Marudu district in Sabah, Malaysia. DNA was extracted 
from filter paper samples of 145 symptomatic patients 
using the FP-chelex rapid protocol, assayed using 
HtLAMP-Pg and HtLAMP-Pf and resulted were inter-
preted visually and confirmed with a portable spectro-
photometer. Following a 3-day training workshop for 
local malaria staff on performance and interpretation of 
HtLAMP assay results, a questionnaire was completed on 
challenges of performing the HtLAMP assay in a regional 
laboratory setting.
Results
Limits of detection of HtLAMP
The HtLAMP limit of detection was dependent on sam-
ple type, i.e. whole blood or filter paper, DNA extraction 
method and the LAMP primer used (Plasmodium genus 
primers PgID19 or P. falciparum primers Pf869 [23]) 
(Table 1). In the HtLAMP platform, overall, the Plasmo-
dium genus LAMP primers (HtLAMP-Pg) performed 
with a better analytical sensitivity than the P. falciparum 
LAMP primers (HtLAMP-Pf). For whole blood 10 and 20 
µL, the chelex-saponin DNA extraction protocol resulted 
in better analytical sensitivity compared to using chelex 
alone. The explanation for the discrepancy in results for 
whole blood 5  µL for the two extraction protocols are 
unclear but may include pipetting error of blood at small 
volumes and partial loss of red cell pellet during the DNA 
extraction process. The best analytical sensitivity for 
HtLAMP-Pg was achieved using 10  µL of whole blood 
with the WB-chelex saponin protocol. This had a LOD of 
2.5 parasites/µL which was equal to the nested PCR used. 
The best LOD for HtLAMP-Pf was 5 parasites/µL using 
20  µL of whole blood with the WB-chelex saponin pro-
tocol. This was equal to the LOD for HtLAMP-Pg at this 
volume, while nested PCR had an LOD of 0.5 parasite/µL.
For filter paper, the standard chelex protocol, with an 
overnight incubation step performed better than the rapid 
protocol with a 2  h incubation step, providing a tenfold 
lower (LOD) for HtLAMP-Pg, i.e. 2.5 parasites/µL com-
pared to 25 parasites/µL. For filter paper samples, the LOD 
for HtLAMP-Pg using the FP-standard chelex protocol for 
DNA extraction was 2.5 parasites/µL, while the sensitivity 
of HtLAMP-Pg using the FP-rapid chelex protocol was 25 
parasites/µL. The HtLAMP-Pf assay was able to detect 5 
parasites/µL using the FP-standard chelex protocol and 50 
parasites/µL using the FP-rapid chelex protocol. Therefore, 
the FP rapid chelex protocol appears to trade-off analytical 
sensitivity for a faster turnaround time for the assay. Taken 
together, these results confirm that the starting sample 
material and method of DNA processing have important 
effects on the analytical sensitivity of the HtLAMP assay.
In the interest of improving turnaround time of the 
assay the FP- rapid chelex protocol was chosen despite a 
compromise in analytical sensitivity for the validation of 
the HtLAMP platform on filter paper samples from PNG 
and field testing in Sabah.
Optimal wavelength for developing an objective threshold 
for positive results
When interrogated across the visible spectrum of light, 
wavelengths between 600 and 650 nm, appeared to best 
distinguish positive from negative samples, whether 
the cloudy magnesium pyrophosphate precipitate was 
present or not and whether there was a blue or pur-
ple colour change associated with HNB (Fig.  2). The 
wavelength of 600  nm was chosen to provide OD val-
ues for the HtLAMP assay for the following reasons; (a) 
this value produced OD values that discriminated well 
between cloudy and blue positive HtLAMP reactions 
and clear and purple negative samples in order to cal-
culate an objective OD threshold for each plate of sam-
ples and (b) a 600 nm filter is a standard setting for many 
bench top spectrophotometers. Table  2 shows the cor-
relation between the visually detected colour change and 
Table 1 Summary of  limits of  detection for  HtLAMP-Pg and  HtLAMP-Pf for  whole blood and  filter paper with  different 
DNA extraction protocols
Sample (n = 4) DNA extraction protocol Limit of detection  
nested PCR (parasites/µL)
Limit of detection  
HtLAMP‑Pg (parasites/µL)
Limit of detection 
HtLAMP‑Pf (parasites/µL)
Whole blood 5 µL WB-chelex 5 5 50
WB-chelex-saponin 25 50 50
Whole blood 10 µL WB-chelex 2.5 25 50
WB-chelex-saponin 2.5 2.5 50
Whole blood 20 µL WB-chelex 25 50 50
WB-chelex-saponin 0.5 5 5
Filter paper 5 µL Chelex standard  
protocol (overnight)
2.5 2.5 5
Chelex rapid protocol (2 h) 5 25 50
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corresponding OD-derived threshold values for the inter-
pretation of HtLAMP-Pf results for a subset of samples 
from the field validation study in Sabah. 
Effect of pH, magnesium sulphate and calcium chloride 
on HNB colour change
The colour change associated with HNB was significantly 
affected by changes in pH, magnesium and calcium. At 
pH 3, HNB had a pink appearance compared with dark 
blue at pH 7 and sky blue at pH 10. Colour variation was 
also seen with magnesium, ranging from pink at a con-
centration of 0.001 M concentration to dark purple at a 
concentration of 1.0  M, and calcium, from dark pink at 
0.01 M concentration to bright blue at 0.5 M concentra-
tions. This suggests that maintaining the correct concen-
tration of calcium, magnesium and pH of the mastermix, 
as well as awareness of other metal ions present during 
extractions processes, is important in allowing HNB to 
undergo its colour change during a LAMP reaction.
Sensitivity and specificity of HtLAMP‑Pg and HtLAMP‑Pf 
in clinical samples from symptomatic patients for the 
detection of P. falciparum
Filter paper blood spots from symptomatic patients 
from Papua New Guinea and Sabah, Malaysia and 
whole blood samples from The Gambia were evaluated 
using HtLAMP-Pg and HtLAMP-Pf to determine the 
diagnostic accuracy of the assay for the detection of P. 
falciparum. The features of each of these sample sets 
and composite sensitivity and specificity of HtLAMP-
Pg/Pf for the detection of P. falciparum are outlined in 
Table 3.
Overall, HtLAMP-Pg had a sensitivity of 98  % 
(n  =  260/266, 95  % CI 95–99) and specificity of 83  % 
(n  =  15/18, 95  % CI 59–96) for the detection of Plas-
modium species. HtLAMP-Pf had a sensitivity of 97  % 
(n  =  124/128, 95  % CI 92–99) and specificity of 96  % 
(n  =  151/157, 95  % CI 92–99) for the detection of P. 
falciparum.
Fig. 2 Optical density values across the visible spectrum of light for HtLAMP samples with and without HNB. Between the wavelengths of 
550–650 nm higher optical densitometry readings were found for samples that were positive by HtLAMP (no HNB positive and HNB positive). In 
addition, at these wavelengths, the optical densitometry readings were also able to distinguish samples that were positive due to the presence of 
the magnesium pyrophosphate precipitate (no HNB positive) and samples that were by positive by HtLAMP due to the blue colour change associ-
ated (HNB positive)
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Sensitivity and specificity of the combination 
of HtLAMP‑Pg and HtLAMP‑Pf for the detection 
of non‑falciparum Plasmodium mono‑infection 
in symptomatic patients
The diagnostic accuracy of the combination of 
HtLAMP-Pg and HtLAMP-Pf for the detection of 
non-falciparum Plasmodium species mono-infections 
was also assessed. In this context, the sensitivity of 
HtLAMP-Pg was 100 % (n = 232/232, 95 % CI 98–100), 
with a specificity of 83 % (n = 15/18, 95 % CI 56–96).
Subgroup analysis demonstrated that in the Papua 
New Guinea samples, HtLAMP-Pg had a sensitivity 
of 100 % (n =  9/9, P. vivax positive) and specificity of 
81 % (n = 13/16). There were 3 false positive HtLAMP-
Pg results. HtLAMP-Pf was negative in all the mono-
infection samples. For the 128 non-falciparum species 
infections from Sabah, HtLAMP-Pg had a sensitivity 
of 100  % (n =  128/128). HtLAMP-Pf was negative for 
122 of these samples. For the 6 false positive HtLAMP-
Pf results (five P. vivax, one P. knowlesi) there was no 
evidence of P. falciparum co-infection by PCR. In the 
Gambia samples, of the 95 HtLAMP-Pg positive sam-
ples, only 1 was negative by HtLAMP-Pf, suggesting 
a non-falciparum species mono-infection which was 
confirmed by PCR to be P. malariae with a parasitae-
mia of 7.5 parasites/µL.
Sensitivity of HtLAMP in persons with asymptomatic 
parasitaemia
Features of the 25 samples chosen from a set of samples 
from asymptomatic school children in Kumasi, Ghana 
are outlined (see Additional file  1). Of the 25 samples 
100 % were positive for P. falciparum by nested PCR and 
44  % were co-infected with P. malariae. Interestingly, 
HtLAMP-Pg was positive for two samples in which only 
P. falciparum gametocytes were seen on microscopy of 
which one was also positive by HtLAMP-Pf. Compared 
with nested PCR the sensitivity of HtLAMP-Pg was 96 % 
(n = 24/25, 95 % CI 80–100) and sensitivity of HtLAMP-
Pf was 88  % (n  =  22/25, 95  % CI 69–97) (Table  4). 
HtLAMP-Pg and HtLAMP-Pf were able to detect the 
samples with the lowest parasitaemia of 40 parasites/µL 
(n = 3).
Feasibility of field application of HtLAMP
HtLAMP was performed in a regional hospital laboratory 
in Kota Marudu district, Sabah, Malaysian Borneo. This 
laboratory was able to perform basic haematology and 
biochemistry testing but did not perform microbiologi-
cal culture or molecular assays. The HtLAMP assay was 
performed in a plastic bucket adapted to function as a 
water bath using a heating element and thermometer. A 
portable spectrophotometer (ChroMate) with a 600  nm 
Table 2 HtLAMP-Pf optical densitometry (OD) results for 77 filter paper samples demonstrating the correlation between the 
visually detected colour change results for positive samples and their correlation with the positive results based on an OD-
derived threshold value
1 2 3 4 5 6 7 8 9 10 11 12
A 29 154 19 17 22 27 34 23 180 32 42 176 0.225
0.374 0.229 0.256 0.257 0.219 0.217 0.252 0.244 0.344 0.243 0.296 0.333 0.235
0.112 -0.033 -0.006 -0.005 -0.043 -0.045 -0.01 -0.018 0.082 -0.019 0.034 0.071 0.218
B 46 30 35 66 36 47 41 52 48 186 53 54 0.224
0.248 0.327 0.234 0.342 0.238 0.241 0.239 0.23 0.217 0.216 0.231 0.366 0.263
-0.014 0.065 -0.028 0.08 -0.024 -0.021 -0.023 -0.032 -0.045 -0.046 -0.031 0.104 0.215
C 65 51 72 73 62 84 67 70 90 74 92 0.208
0.232 0.246 0.232 0.225 0.338 0.333 0.256 0.224 0.246 0.366 0.228 0.31 0.243
-0.03 -0.016 -0.03 -0.037 0.076 0.071 -0.006 -0.038 -0.016 0.104 -0.034 0.048 0.225
D 77 96 81 85 194 89 100 101 95 68 106 0.239
0.231 0.217 0.248 0.217 0.226 0.243 0.235 0.257 0.357 0.22 0.317 0.236 0.242
-0.031 -0.045 -0.014 -0.045 -0.036 -0.019 -0.027 -0.005 0.095 -0.042 0.055 -0.026 0.262
E 159 122 131 124 127 94 136 129 105 187 142
0.248 0.218 0.221 0.225 0.225 0.212 0.312 0.208 0.213 0.304 0.227 0.211
-0.014 -0.044 -0.041 -0.037 -0.037 -0.05 0.05 -0.054 -0.049 0.042 -0.035 -0.051
F 137 147 149 189 141 112 146 157 112(1) 160 198
0.252 0.237 0.22 0.209 0.224 0.213 0.207 0.228 0.225 0.227 0.301 0.274
-0.01 -0.025 -0.042 -0.053 -0.038 -0.049 -0.055 -0.034 -0.037 -0.035 0.039 0.012
G 115 116 177 119 178 181 123 151
0.263 0.232 0.215 0.211 0.21 0.202 0.199 0.211 0.208 0.191 0.263 0.216
0.001 -0.03 -0.047 -0.051 -0.052 -0.06 -0.063 -0.051 -0.054 -0.071 0.001 -0.046
H pos pos NTC NTC NTC NTC
0.407 0.385 0.243 0.225 0.223 0.239 0.242 0.27 0.261 0.207 0.19 0.175
0.145 0.123 -0.019 -0.037 -0.039 -0.023 -0.02 0.008 -0.001 -0.055 -0.072 -0.087
Samples in blue had a blue/cloudy colour change as well as a corresponding positive OD threshold value. Samples in yellow were positive only by OD threshold. 
Shaded grey wells were negative controls within the plate. OD values for all negative control samples in each plate are used to calculate the OD threshold value (mean 
plus two standard deviations) which in this example is 0.262
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filter provided the optical densitometry values. Samples 
and HtLAMP reagents were stored at −20 °C in a freezer. 
Three separate benches within a large room were dedi-
cated to DNA extraction, HtLAMP assay setup and spec-
trophotometry in order to prevent cross-contamination.
The HtLAMP-Pg assay, performed in this resource-
limited laboratory setting, had a sensitivity of 100  % 
(n =  145/145, 95  % CI 97–100). The HtLAMP-Pf assay 
had a sensitivity of 100 % (n =  17/17, 95 % CI 80–100) 
and a specificity of 95 % (n = 123/128, 95 % CI 90–98).
Two local malaria laboratory staff was trained over 
a 3  day period to perform DNA extraction from filter 
paper and whole blood, setup the assay and interpret the 
results of the HtLAMP assay. Issues that were identified 
by local staff as potential limitations to deployment of 
HtLAMP in a field laboratory were difficulty of accurate 
sample placement into the 96-well plate and the availabil-
ity and cost of reagents. However, it was felt that these 
limitations were balanced against the rapid turnaround 
time for the detection of parasites in microscopy nega-
tive samples thereby facilitating earlier patient treatment 
and household screening, potential time and cost saving 
in avoiding sending samples for PCR testing at reference 
laboratories and ease of interpretation of visual colour 
change results on the HtLAMP assay. The main chal-
lenges to setting up HtLAMP in this non-reference, low 
resource setting laboratory were ensuring good workflow 
to prevent contamination, and ensuring the reliability of 
ancillary equipment such as the centrifuge and freezers.
Discussion
To achieve its ambitious goals, the malaria elimination 
agenda will likely require diagnostic capacity to actively 
identify sub-patent infection in order to interrupt trans-
mission. PCR, the most sensitive molecular diagnostic 
tool currently available, is limited by its technical require-
ments, particularly in resource limited field settings. A 
robust, low-cost and high-throughput assay for the rapid 
detection of malaria parasite DNA in finger-prick blood 
samples would provide this capacity. LAMP has been 
adapted into several different platforms [16, 31, 42–44] 
in order to improve its field applicability and throughput. 
While the definition of the throughput required for the 
application of LAMP for the purpose of malaria elimina-
tion remains to be established, the number of samples 
able to be processed simultaneously on these platforms 
range from 5 [42] to 46 [31, 44] per assay.
The HtLAMP assay for the diagnosis of malaria that 
is described here has a simple platform—a standard 
96-well microtitre plate, covered with a clear plate seal 
and incubated in a water bath at 65  °C, that is able to 
process a minimum of 85 samples (allowing for positive 
and negative controls). The use of a colorimetric indica-
tor enhances visual detection of the assay endpoint. To 
improve objectivity of interpretation of results, the assay 
uses a spectrophotometer at 600 nm to produce a thresh-
old value which correlates with the visible colour change. 
In addition, DNA extraction protocols for whole blood 
and filter paper based on chelex and saponin have been 
modified to improve turnaround time while maintaining 
the cost effectiveness of the assay.
However, there appears to be significant variation in 
the LOD of HtLAMP depending on sample type, DNA 
extraction method and primers selected, particularly 
so for filter paper samples where there was a ten-fold 
loss of analytical sensitivity using a DNA extraction 
method that had a faster turnaround time. Neverthe-
less, HtLAMP-Pg using 10  µL of whole blood with a 
chelex saponin protocol and HtLAMP-Pg on a 5 µL fil-
ter paper blood spot using the chelex overnight protocol 
achieved a LOD of 2.5 parasites/µL. This suggests that 
the HtLAMP platform has the potential to reach the 
WHO target LOD. However, further modifications, such 
as using commercial kits, optimisation of low cost DNA 
extraction methods or using a larger volume of blood 
are likely to be required to achieve the balance between 
improved analytical sensitivity and turnaround time. The 
availability of more sensitive LAMP primers to detect 
Plasmodium genus and species- specific primers may 
also enhance the LOD of the HtLAMP assay. Therefore, 
malaria elimination programs choosing diagnostic tools 
may be required to make important operational and 
logistics decisions with regards to both the type of assay 
used and the sample types, for example whole blood or 
filter paper, that can achieve the best analytical sensitiv-
ity for that assay in order to meet the current WHO tar-
get of 2 parasites/µL.
The HtLAMP assay has been validated in a resource 
limited laboratory setting using filter paper samples 
and the chelex rapid DNA extraction protocol, despite 
its aforementioned limitations, in order to evaluate its 
turnaround time in this clinical setting. Compared with 
PCR, which requires samples to be sent to a reference 
laboratory, HtLAMP-Pg had a sensitivity of 100  % and 
HtLAMP-Pf had a sensitivity of 100 % and a specificity of 
95 % and results were available within 24 h.
Table 4 Sensitivity and  specificity of  HtLAMP compared 
with nested PCR in Ghanaian children with asymptomatic 
parasitaemia
Sensitivity PPV
HtLAMP-Pg (compared  
with nested PCR)
96 % (24/25)
95 % CI 80–100
100 %
95 % CI 85–100
HtLAMP-Pf (compared  
with nested PCR)
88 % (22/25)
95 % CI 69–97
100 %
95 % CI 85–100
Page 10 of 12Britton et al. Malar J  (2015) 14:335 
In this study, the HtLAMP assay was validated for 
the detection of Plasmodium genus and P. falciparum 
on clinical samples from microscopy positive sympto-
matic and asymptomatic patients from regions with 
different Plasmodium species prevalence. Overall, 
HtLAMP-Pg had a sensitivity of 98  % and specificity 
of 83 % and HtLAMP-Pf had a sensitivity of 97 % and 
specificity of 96  % for the detection of P. falciparum. 
The use of the combination of Plasmodium genus and 
P. falciparum LAMP primers showed a HtLAMP-Pg 
sensitivity of 100  % and specificity 83  % compared 
to PCR for the detection of non-falciparum Plasmo-
dium monoinfections. These results are compara-
ble to other LAMP studies in symptomatic patients 
(Table  5). However, further studies are required to 
determine the sensitivity and specificity of HtLAMP 
in detecting sub-microscopic infections in asympto-
matic patients.
The 96 well HtLAMP platform is able to test 85 sam-
ples per plate, allowing for positive and negative controls. 
The cost per test in this platform is USD$ 0.85 exclud-
ing primers and DNA extraction. Final cost will depend 
on the starting material (filter paper or whole blood), the 
use of either crude or commercial DNA extraction pro-
tocols and the primer sets selected. Nevertheless, the 
cost per sample to perform HtLAMP-Pg on whole blood 
extracted using chelex-saponin protocol is USD$1. The 
turnaround time for completion of an assay, including 
DNA extraction, is 4–6 h.
However, HtLAMP is not a quantitative assay, a limi-
tation it shares with other LAMP based assays. Other 
potential limitations include the use of HNB, which is 
sensitive to changes in pH and metal ion concentrations. 
Awareness of, for example, the type of DNA extraction 
method used on samples, which may contain reagents 
that affect pH and metal ion concentrations, would help 
maintain the reliability of interpretation of the colour 
change aspect of the assay. Nevertheless, this is balanced 
against its low cost, stability at room temperature and 
easy visual interpretation of results. In its current for-
mat, HtLAMP relies on the storage of reagents at −20 °C. 
While an important issue in terms of field deployment, 
this could potentially be overcome by lyophilization of 
reagents.
Conclusion
The HtLAMP platform offers several important 
improvements over currently available LAMP plat-
forms. Firstly, HtLAMP is able to process up to 85 
samples simultaneously which makes it an ideal poten-
tial platform for surveillance or household surveys. 
Secondly, it uses standard consumables, and can be 
performed using DNA extracted by chelex and sapo-
nin based protocols which makes it very cost effective. 
Thirdly, one of the significant advantages to the use of 
HNB is that it can be added to the start of the assay 
such that HtLAMP remains a closed system, thereby 
reducing the risk of cross-contamination. Fourthly, 
while the platform of HtLAMP has been used here 
with Plasmodium genus and P. falciparum primers, 
it could be adapted to detect any other blood-borne 
pathogen of interest, thereby broadening the poten-
tial applications of the platform beyond the diagnosis 
of malaria. Finally, HtLAMP has been performed suc-
cessfully in a regional laboratory setting by local staff 
trained over a very short period of time demonstrating 
its ease of performance and interpretation of results.
This provides confidence that the HtLAMP could be 
usefully deployed as a molecular diagnostic tool to sup-
port malaria elimination in resource-limited settings.
Table 5 Comparison of  sensitivity and  specificity of  HtLAMP-Pg and  HtLAMP-Pf for  the detection of  P. falciparum 
and non-falciparum species with other LAMP studies in symptomatic patients
LAMP study Sample source Species LAMP primer Sensitivity (%) Specificity (%)
HtLAMP Symptomatic patients P. falciparum Pg 98 83
Pf 97 96
Polley et al. [23] Symptomatic patients P. falciparum Pg 93.9 100
Pf 93.3 100
Polley et al. [27] Symptomatic returned travellers P. falciparum Pg 97 99.2
Pf 98.4 98.1
Hopkins et al. [30] Passive case detection P. falciparum Pf 89–93.9 76.3–85
HtLAMP Symptomatic patients Non-falciparum Pg 100 83
Vallejo et al. [32] Symptomatic patients Non-falciparum Pg 91.4 91.8
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